New German-based CRO Enters OTC Sector
A new provider of clinical studies and strategic consulting, Orange OTC Research, aims to shake up the market for over-the-counter (OTC) medicines and related products.
A new provider of clinical studies and strategic consulting, Orange OTC Research, aims to shake up the market for over-the-counter (OTC) medicines and related products.
The company claims to be the first clinical research organization (CRO) to focus specifically on consumer healthcare in Europe, and hopes to become an
initiator of “new, intelligent, scientifically supported product claims,” according to co-founder Dr. Stefan Sandner, from the pharmaceutical service provider Diapharm GmbH & Co. KG.
The other people behind the venture are Juliane Hellhammer, from the
CRO daacro GmbH & Co. KG, and Dr. Burkhard Breuer and Dr. Marion Breuer from the CRO proinnovera GmbH.
The partners intend to pool their expertise as CROs and consultants with the aim of counteracting the trend towards standardized OTC product profiles in the long term. Their goal is to create new market opportunities for consumer healthcare products through creative study designs and the use of state-of-the-art technology, explained Hellhammer.
“Our OTC studies are based on valid medical and scientific support, along with study designs that are customized to meet these products’ special market needs. This is a significant added benefit compared to conventional marketing studies,” she said.
The company’s strategic approach and its specialization as a consumer healthcare CRO for OTC medicinal products and related health products, such as nutraceuticals and cosmeceuticals, is a first in Europe, according to the partners. As a result, Orange OTC Research is playing a pioneering role in making consumer healthcare products a category to take seriously, Sandner added.
“Through the combination of sound market knowledge, regulatory OTC expertise and customized studies, we are now giving manufacturers the opportunity to position products and brands off the beaten track thanks to innovative claims that are in line with regulatory and medical requirements.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
